Jazz Pharmaceuticals plc
JAZZ
$181.37
-$0.65-0.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.27B | 4.16B | 4.09B | 4.06B | 4.07B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.27B | 4.16B | 4.09B | 4.06B | 4.07B |
| Cost of Revenue | 432.81M | 410.81M | 393.54M | 387.17M | 378.98M |
| Gross Profit | 3.83B | 3.75B | 3.69B | 3.68B | 3.69B |
| SG&A Expenses | 1.69B | 1.65B | 1.60B | 1.58B | 1.42B |
| Depreciation & Amortization | 654.66M | 643.82M | 632.91M | 626.03M | 627.31M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.53B | 3.48B | 3.40B | 3.40B | 3.27B |
| Operating Income | 739.61M | 675.53M | 684.23M | 664.71M | 795.87M |
| Income Before Tax | -628.59M | -703.80M | -512.27M | 361.29M | 468.69M |
| Income Tax Expenses | -272.44M | -335.32M | -107.43M | -120.91M | -91.43M |
| Earnings from Continuing Operations | -356.15 | -368.48 | -404.84 | 482.20 | 560.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -356.15M | -368.48M | -404.84M | 482.20M | 560.12M |
| EBIT | 739.61M | 675.53M | 684.23M | 664.71M | 795.87M |
| EBITDA | 1.44B | 1.36B | 1.36B | 1.33B | 1.46B |
| EPS Basic | -5.78 | -5.96 | -6.60 | 7.82 | 9.11 |
| Normalized Basic EPS | 5.55 | 4.79 | 4.74 | 4.38 | 5.56 |
| EPS Diluted | -5.97 | -6.07 | -6.73 | 7.50 | 8.79 |
| Normalized Diluted EPS | 5.42 | 4.73 | 4.66 | 4.16 | 5.34 |
| Average Basic Shares Outstanding | 243.93M | 243.41M | 244.13M | 245.81M | 247.37M |
| Average Diluted Shares Outstanding | 247.21M | 245.28M | 246.85M | 255.28M | 256.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |